The posting
About Cahira Technologies
Cahira has created the world’s first non-surgical, wireless nano-electronic implants that cross the intact blood-brain barrier, enabling neuromodulation with high precision. Having validated the platform in vivo (mice), we are preparing to choose a beach-head indication (BHI) and move rapidly toward first-in-human studies and commercialization.
Role Summary
Lead the human-translation roadmap and the indication-prioritization process for our nano-implant platform. Exposure to AI/ML-enabled algorithms or digital companions integrated with implants is preferred. This role spans late pre-clinical work through global regulatory approvals and launch:
- Select and justify the beach-head disease indication that maximizes probability of clinical success, speed to market, reimbursement viability, and strategic value.
- Build and execute the regulatory & clinical strategy (FDA, EU MDR, and key ROW jurisdictions).
- Define and drive the milestone plan from technology advancement and GLP studies to pivotal trials and market approval.
Required Qualifications
- 10+ years in Class III active implantable devices with ≥5 years in neural implants, neuromodulation, or neurostimulation.
- Direct, end-to-end experience bringing at least one neural or active implantable device from late pre-clinical through FDA approval and commercial launch.
- Demonstrated leadership of indication-selection or product-market-fit efforts for a platform technology.
- Deep knowledge of FDA IDE, PMA, De Novo, Breakthrough Devices Program, Q-Subs, and EU MDR processes.
- Hands-on expertise in design-control, risk-management, biocompatibility, and electrical safety standards relevant to neural implants.
- Advanced degree (PhD, MD, MS, or equivalent) in Biomedical Engineering, Neuroscience, Regulatory Affairs, or related discipline.
- Outstanding written and verbal communication skills for regulatory dossiers, investor updates, and KOL engagement.
Preferred Qualifications
- Experience with nano-scale or wirelessly powered implants.
- Obtained Breakthrough Device Designation or HDE for a neurotechnology product.
- Established network of FDA reviewers, neurology / neurosurgery investigators, and reimbursement experts.
- RAC (US/EU) or PMP certification.
- Familiarity with health-economic modeling and payer evidence requirements for neuromodulation therapies.
- Exposure to AI/ML-enabled algorithms or digital companions integrated with implants.
- Thrives in a fast-paced, resource-constrained startup environment and can scale teams rapidly.



